Upload
prezi22
View
1.354
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Citation preview
Phase 1 Pre-vaccination
Training February 26, 2003
MaineMaine
Public Health Response TeamPublic Health Response Team
Office of Public Health Emergency Preparedness
Anthony J. Tomassoni, MD, MS, FACEP, DACMTAnthony J. Tomassoni, MD, MS, FACEP, DACMTMedical DirectorMedical Director
[email protected]@Maine.gov
Steven Trockman, MPH, CHESSteven Trockman, MPH, CHESCoordinatorCoordinator
[email protected]@Maine.gov
Janet AustinJanet AustinPlanning & Research Associate IIPlanning & Research Associate II
[email protected]@Maine.gov
Phase 1 Pre-vaccination Objectives Explain need for public health and Explain need for public health and
hospital smallpox response teamshospital smallpox response teams
Assess smallpox vaccination risks Assess smallpox vaccination risks and screen for contraindicationsand screen for contraindications
Phase 1 Pre-vaccination Objectives Describe smallpox vaccination Describe smallpox vaccination
administration procedureadministration procedure
Define how to care for smallpox Define how to care for smallpox vaccination sitevaccination site
Identify the “take” after vaccination Identify the “take” after vaccination
Phase 1 Pre-vaccination Objectives Recognize smallpox vaccination Recognize smallpox vaccination
common and serious adverse common and serious adverse reactions reactions
Explain the procedures for reporting Explain the procedures for reporting adverse reactions and receiving care adverse reactions and receiving care
List vaccination plan next stepsList vaccination plan next steps
CDC VIDEO
SMALLPOX SMALLPOX Vaccine AdministrationVaccine Administration
37:12 minutes37:12 minutes
Need for public health and hospital smallpox response teams
Smallpox
Smallpox is a severe, febrile, contagious, Smallpox is a severe, febrile, contagious, sometimes fatal disease caused by the virus sometimes fatal disease caused by the virus “variola” that is characterized by a vesicular and “variola” that is characterized by a vesicular and pustular eruption.pustular eruption.
Why fear smallpox as BW?
Case fatality rate of 30% +Case fatality rate of 30% + No specific therapyNo specific therapy Infectious dose is smallInfectious dose is small Transmission rate of 1:10-20Transmission rate of 1:10-20
Why fear smallpox?
Used in the past as a BWUsed in the past as a BW Smallpox invokes terrorSmallpox invokes terror Weaponized; stable in aerosol formWeaponized; stable in aerosol form Worldwide vaccination ended 1980:Worldwide vaccination ended 1980:
Routine smallpox vaccination discontinued in Routine smallpox vaccination discontinued in America in 1971; not required for America in 1971; not required for international travel since 1981.international travel since 1981.
Diagnosis and Management of Smallpox NEJM 346;17:1300-1308 April 25, 2002Joel G. Breman, MD, DTPH, and D.A. Henderson, MD, MPH
Last Case of Variola Major in the World
Rahima BanuRahima Banu
Bhola Island, October 16, 1975Bhola Island, October 16, 1975
Terrorist Smallpox Event
A case of smallpox anywhere in the A case of smallpox anywhere in the worldworld
““The discovery of a single suspected The discovery of a single suspected case of smallpox must be treated as case of smallpox must be treated as an international health emergency an international health emergency and be brought immediately to the and be brought immediately to the attention of national officials through attention of national officials through local and state health authorities.”local and state health authorities.”
Consensus Statement: Smallpox as a Biological Weapon, Consensus Statement: Smallpox as a Biological Weapon, JAMAJAMA. 1999; 281: . 1999; 281: 2131.2131.
Smallpox TREATMENT
Vaccinia vaccination by the 4Vaccinia vaccination by the 4 thth day day of exposure. of exposure.
No specific anti-viral therapy No specific anti-viral therapy proven effective in clinical proven effective in clinical smallpox disease.smallpox disease.
Vistide® (cidofovir)
Cidofovir unknown Cidofovir unknown benefit against smallpoxbenefit against smallpox
Toxic side-effectsToxic side-effects
Not FDA approved for Not FDA approved for use in treatment of use in treatment of smallpoxsmallpox
ME smallpox vaccination plan
General Concepts
Vaccination targeted to Public Health Vaccination targeted to Public Health Smallpox Response Teams and hospital-Smallpox Response Teams and hospital-based Healthcare Smallpox Response based Healthcare Smallpox Response TeamsTeams
Sites established considering population Sites established considering population density, hospital clusters, judicious use of density, hospital clusters, judicious use of vaccine, vaccine security, and accessibilityvaccine, vaccine security, and accessibility
Calendar
11/21/02 Request to states for pre-event and 11/21/02 Request to states for pre-event and post-event smallpox plans due 12/9/02post-event smallpox plans due 12/9/02
12/26/02 Maine Bureau of Health invites 12/26/02 Maine Bureau of Health invites volunteers for Phase 1 - Public Health volunteers for Phase 1 - Public Health Response TeamsResponse Teams
Arrival in ME: Jan. 28
Calendar: screening
2/18/03 Smallpox volunteers receive email 2/18/03 Smallpox volunteers receive email pre-vaccination screening instructions pre-vaccination screening instructions
2/19/03 Workplace Health screening starts2/19/03 Workplace Health screening starts
VACCINE CONTRAINDICATIONS
Eczema or atopic dermatitisEczema or atopic dermatitis Active skin conditionsActive skin conditions Weakened immune systemWeakened immune system PregnancyPregnancy Eye diseaseEye disease
Serious allergic reaction to a prior dose of Serious allergic reaction to a prior dose of DryvaxDryvax®® vaccine or vaccine component vaccine or vaccine component polymyxin Bpolymyxin B streptomycinstreptomycin tetracyclinetetracycline neomycinneomycin phenolphenol
VACCINE CONTRAINDICATIONS
VACCINE CONTRAINDICATIONS
Eczema/Atopic Dermatitis:Eczema/Atopic Dermatitis: Rash involves flexures Rash involves flexures Two of the following:Two of the following:
Rash started before age 5Rash started before age 5Personal history of allergies (food/env) Personal history of allergies (food/env)
or asthmaor asthmaFirst degree relative with atopic First degree relative with atopic
dermatitisdermatitis
VACCINE CONTRAINDICATIONS
Allergic to the vaccineAllergic to the vaccine Younger than 12 months of ageYounger than 12 months of age Moderate or severe short-term illnessModerate or severe short-term illness Currently breastfeedingCurrently breastfeeding
Smallpox Vaccine
NYC Board of HealthNYC Board of HealthLive Vaccinia VirusLive Vaccinia Virus
DryvaxDryvax®®
Wyeth LaboratoriesWyeth Laboratories
VACCINE INDICATIONS
People who have been People who have been directly exposeddirectly exposed to the to the
smallpox virus should get the smallpox virus should get the vaccinevaccine, , regardless of their regardless of their
health statushealth status..
Vaccinia Vaccinia virus is a poxvirus. Vaccinia virus is a poxvirus.
Vaccinia is related to variola but milder.Vaccinia is related to variola but milder.
Antigenic similarity allows for cross-reactivity enabling Antigenic similarity allows for cross-reactivity enabling vaccinia vaccination to protect against smallpox.vaccinia vaccination to protect against smallpox.
Vaccinia virus may cause rash, fever, and head and body Vaccinia virus may cause rash, fever, and head and body aches. In certain groups of people, complications from aches. In certain groups of people, complications from the vaccinia virus can be severethe vaccinia virus can be severe. .
Vaccinia: “Live Virus” Vaccine
Contains a "living" virus that is able to give Contains a "living" virus that is able to give and produce immunity, usually without and produce immunity, usually without causing illnesscausing illness
Care of the site important to prevent Care of the site important to prevent transmission to other parts of the body or to transmission to other parts of the body or to other peopleother people
Live virus vaccines effective and safe for most Live virus vaccines effective and safe for most people with healthy immune systems people with healthy immune systems
Sometimes experience mild symptoms post-Sometimes experience mild symptoms post-vaccination vaccination
Other live virus vaccines: measles, mumps, Other live virus vaccines: measles, mumps, rubella, chickenpoxrubella, chickenpox
Smallpox Vaccination: Immunity
High level immunity for 3 to 5 years. High level immunity for 3 to 5 years.
Immunity wanes after 10 years. Immunity wanes after 10 years. Revaccination recommended every 10 Revaccination recommended every 10 years for continued protection.years for continued protection.
Stable antibodies during a 30-year period Stable antibodies during a 30-year period in vaccinees at birth, age 8 and 18 years.in vaccinees at birth, age 8 and 18 years.
Smallpox Vaccination: Immunity Vaccination within 3 days of exposure will Vaccination within 3 days of exposure will
prevent or significantly lessen the severity prevent or significantly lessen the severity of smallpox symptoms in the vast majority of smallpox symptoms in the vast majority of people. of people.
Vaccination 4 to 7 days after exposure Vaccination 4 to 7 days after exposure likely offers some protection from disease likely offers some protection from disease or may modify the severity of disease. or may modify the severity of disease.
Calendar: training
2/26/03 Phase 1 Pre-vaccination training (2 2/26/03 Phase 1 Pre-vaccination training (2 hours)hours)
Second session date TBD (makeup if Second session date TBD (makeup if needed) needed)
Phase 1 Vaccination
Clinics 3/3 and 3/6 (makeup/overflow)Clinics 3/3 and 3/6 (makeup/overflow)
Smallpox Vaccination Method
Multiple Puncture Vaccination Using Bifurcated NeedleMultiple Puncture Vaccination Using Bifurcated Needle
Step-by-Step Method for Vaccination
1. Skin Preparation: None.1. Skin Preparation: None.
**Under no circumstances Under no circumstances should alcohol be applied should alcohol be applied to the skin prior to to the skin prior to vaccinationvaccination * *
Step-by-Step Method for Vaccination
2. Dip Needle2. Dip NeedleThe needle is dipped into the vaccine vial and withdrawn. The needle is dipped into the vaccine vial and withdrawn. The needle is designed to hold a minute drop of vaccine of The needle is designed to hold a minute drop of vaccine of sufficient size and strength to ensure a take if properly sufficient size and strength to ensure a take if properly administered. administered.
Step-by-Step Method for Vaccination
3. Make 15 perpendicular insertions 3. Make 15 perpendicular insertions within a 5mm diameter area.within a 5mm diameter area.
Step-by-Step Method for Vaccination
4. Absorb excess vaccine.4. Absorb excess vaccine.
Cover site with sterile dressing
Virus can be recovered at site from time of Virus can be recovered at site from time of papule until scab separatespapule until scab separates
Site should be kept drySite should be kept dry Normal bathing can occur if covered by Normal bathing can occur if covered by
waterproof bandagewaterproof bandage
Vaccination Site Care
Vaccination Site Care
Cover the vaccination site loosely with a gauze Cover the vaccination site loosely with a gauze bandage.bandage.
Wear long-sleeved shirt that covers the Wear long-sleeved shirt that covers the vaccination site.vaccination site.
Change the bandage every 1-2 days. Discard Change the bandage every 1-2 days. Discard bandage waste in plastic bag with “zip” closure.bandage waste in plastic bag with “zip” closure.
Hand washing after any contact with bandage or Hand washing after any contact with bandage or sitesite
Vaccination Site CareKeep the vaccination site dry.Keep the vaccination site dry.
Put the contaminated bandages in a sealed plastic Put the contaminated bandages in a sealed plastic bag and throw them away.bag and throw them away.
Wash clothing or other any material that comes in Wash clothing or other any material that comes in contact with the vaccination site. contact with the vaccination site.
When the scab comes off, throw it away in a When the scab comes off, throw it away in a sealed plastic bag.sealed plastic bag.
Vaccination Site Care Do Do notnot use a bandage that blocks all air from the use a bandage that blocks all air from the
vaccination site. This may cause the skin at the vaccination site. This may cause the skin at the vaccination site to soften and wear away. vaccination site to soften and wear away. Use loose gauze secured with medical tape to Use loose gauze secured with medical tape to
cover the site.cover the site.
Do Do notnot put salves or ointments on the vaccination put salves or ointments on the vaccination site.site.
Do Do notnot scratch or pick at the scab. scratch or pick at the scab.
Vaccinia: Vaccination Site
““Major Reaction” (vs. “Equivocal Major Reaction” (vs. “Equivocal Reaction”)Reaction”)
First VaccinationFirst Vaccination Vesicular or pustular lesionVesicular or pustular lesion Area of definite palpable induration Area of definite palpable induration
surrounding a central crust or ulcersurrounding a central crust or ulcer
WHO Expert Committee on Smallpox, 1964
Clinical Response to Vaccination
RevaccinationRevaccination Less pronounced and more rapid Less pronounced and more rapid
progressionprogression Pustular lesion or induration Pustular lesion or induration
surrounding a central crust or ulcersurrounding a central crust or ulcer
WHO Expert Committee on Smallpox, 1964
Clinical Response to Vaccination
Swelling and tenderness of axillary Swelling and tenderness of axillary lymph nodes, usually during 2lymph nodes, usually during 2ndnd week week
Fever and malaise commonFever and malaise common
Major Reaction
Normal ReactionDay 7
Normal ReactionDay 12
Major ReactionFirst time vaccinee, Day 10
Major ReactionFirst time vaccinee, Day 15
Major ReactionRevaccinee, Day 4
Major ReactionRevaccinee, Day 8
Major ReactionRevaccinee, Day 10
Major ReactionRevaccinee, Day 15
FatigueFatigue HeadacheHeadache MyalgiaMyalgia LymphadenopathyLymphadenopathy LymphangitisLymphangitis PruritisPruritis Edema at the vaccination siteEdema at the vaccination site Satellite LesionsSatellite Lesions
Expected Range of Vaccine Reactions
Rates of Expected Reactions
21% complications required physician consult21% complications required physician consult Most Common SymptomsMost Common Symptoms
Fatigue (50%)Fatigue (50%) Headache (40%)Headache (40%) Muscle aches and Chills (20%)Muscle aches and Chills (20%) Nausea (20%)Nausea (20%) Fever Fever 37.7 37.7 ºC or 100 ºF (10%)ºC or 100 ºF (10%)
Administrative Leave
Do not need to place HCWs on leave, Do not need to place HCWs on leave, unless:unless: Physically unable to work due to Physically unable to work due to
systemic signs and symptomssystemic signs and symptoms Extensive skin lesions or vaccination site Extensive skin lesions or vaccination site
that can not be coveredthat can not be covered HCWs do not adhere to infection control HCWs do not adhere to infection control
precautions and recommendationsprecautions and recommendations
MMWR: Feb 21, 2001/52(02):136
n = 4,213 health-care workers in 27 different cities and counties
7 (~ 0.17 %) nonserious adverse events include: fever (2), rash (2), malaise (2), pruritus (2), hypertension (2) and pharyngitis (2)
US Military Data as of 2/12/03
DoD healthcare workers vaccinated against DoD healthcare workers vaccinated against smallpox: More than 8,000smallpox: More than 8,000
DoD operational forces vaccinated against DoD operational forces vaccinated against smallpox: Well over 100,000smallpox: Well over 100,000
US Military Data as of 2/12/03
Sick Leave (SL) OverallSick Leave (SL) Overall 3% of vaccinated People3% of vaccinated People
- - SL after primary (first)SL after primary (first) 4-5%4-5%
- - SL after revaccinationSL after revaccination 1% to 2%1% to 2%
- Average length of sick - Average length of sick leaveleave
1.5 days1.5 days
Auto-inoculationAuto-inoculation 1 case1 case
Transfer of vaccinia virus to Transfer of vaccinia virus to contactscontacts
0 cases0 cases
Treatments with (VIG)Treatments with (VIG) 0 cases0 cases
Deaths due to smallpox Deaths due to smallpox vaccinationvaccination
0 cases0 cases
Smallpox Vaccine Adverse Reactions
Nonspecific dermatological conditions Nonspecific dermatological conditions Inadvertent inoculationInadvertent inoculation Ocular vacciniaOcular vaccinia Generalized vacciniaGeneralized vaccinia Eczema vaccinatumEczema vaccinatum Progressive vaccinia (vaccinia necrosum)Progressive vaccinia (vaccinia necrosum) Post-vaccinial encephalitisPost-vaccinial encephalitis Fetal vacciniaFetal vaccinia Other Other Not yet characterizedNot yet characterized
Vaccinia: Adverse Reactions
The most frequent adverse The most frequent adverse complication of vaccination is complication of vaccination is inadvertent inoculationinadvertent inoculation at other at other
sites.sites.
Inadvertent Inoculation
Transfer of vaccinia virus from vaccination site Transfer of vaccinia virus from vaccination site to another site on the body, or to a close contactto another site on the body, or to a close contact
Most frequent complication of smallpox Most frequent complication of smallpox vaccinationvaccination
Most common sites are periocular/ocular, face, Most common sites are periocular/ocular, face, nose, mouth, genitalia, rectumnose, mouth, genitalia, rectum
Lesions contain vaccinia virus and follow Lesions contain vaccinia virus and follow vaccination coursevaccination course
Adverse Vaccination Reactions
Accidental ImplantationAccidental Implantation
Inadvertent Inoculation
Hand washing after contact with vaccination Hand washing after contact with vaccination site or contaminated material most effective site or contaminated material most effective preventionprevention
Uncomplicated lesions require no therapy, self-Uncomplicated lesions require no therapy, self-limited, resolve in ~3 weekslimited, resolve in ~3 weeks Risk factors: disruption of epidermis or very Risk factors: disruption of epidermis or very
youngyoung
VIG may speed recovery if extensive or severe VIG may speed recovery if extensive or severe manifestation (e.g., significant pain) manifestation (e.g., significant pain)
Nonspecific rash following smallpox vaccination
Vaccination site
Photo credit: J. Michael Lane, MD MPHCDC Teaching slide set
Adverse reactions following smallpox vaccination
Nonspecific Rashes
Flat, erythematous, macules or patches, and Flat, erythematous, macules or patches, and generalized urticarial rashes generalized urticarial rashes
Usually do not become vesicularUsually do not become vesicular Onset ~ 10 days post-vaccinationOnset ~ 10 days post-vaccination Afebrile patient, well appearing Afebrile patient, well appearing Spontaneously resolves ~2-4 daysSpontaneously resolves ~2-4 days Immune response vs. viral replicationImmune response vs. viral replication Antipruritics Antipruritics
Nonspecific rash following smallpox vaccination
Photo credit: Vaccination reactions in vaccinia-naive volunteers in a clinical study of diluted Dryvax® enrolled in NIAID VTEUs
Photo credit: V. Fulginiti, MD and Logical Imageshttp://www.bt.cdc.gov/training/smallpoxvaccine/reactions/default.htm
ERYTHEMA MULTIFORME
Adverse Vaccination Reactions
Auto-inoculationAuto-inoculation
Ocular Vaccinia May present as blepharitis, conjunctivitis, May present as blepharitis, conjunctivitis,
keratitis, iritis, or combinationkeratitis, iritis, or combination
Should be managed in consultation with an Should be managed in consultation with an ophthalmologistophthalmologist
Treatment may include topical ophthalmic Treatment may include topical ophthalmic topical antiviral agents, topical steroids topical antiviral agents, topical steroids and topical antibacterials and VIGand topical antibacterials and VIG
Secondary Corneal Infection
Adverse Vaccination Reactions
Vaccinia KeratitisVaccinia Keratitis
Adverse Vaccination Reactions
Bacterial InfectionsBacterial Infections
Adverse Vaccination Reactions
Generalized VacciniaGeneralized Vaccinia
Vaccination site
Regional form
Sometimes resemblesSmallpox
Photo credit: J. Michael Lane, MD MPHCDC Teaching slide set
Adverse reactions following smallpox vaccination
GENERALIZED VACCINIA
Adverse Vaccination Reactions
Generalized vacciniaGeneralized vaccinia
Adverse Vaccination Reactions
Eczema VaccinatumEczema Vaccinatum
Multiple umbilicated EV papular lesionsHealed EV
EV predilection for sites of atopic dermatitis (eczema)
Photo credit: V. Fulginiti, MD, H. Kempe MD and Logical Imageshttp://www.bt.cdc.gov/training/smallpoxvaccine/reactions/default.htm
Adverse Vaccination Reactions
Eczema vaccinatumEczema vaccinatum
Adverse Vaccination Reactions
Progressive VacciniaProgressive Vaccinia
““Vaccinia Necrosum/Gangrenosa”Vaccinia Necrosum/Gangrenosa”
““Disseminated Vaccinia”Disseminated Vaccinia”
Adverse Vaccination Reactions
Progressive VacciniaProgressive Vaccinia
Photo credit: J. Michael Lane, MD MPHCDC Teaching slide set Adverse reactions
following smallpox vaccination
Atypical PV in 64yo with lymphoma and
IgA, IgM and IgA deficiency
Severe Take
Severe take
Progressive vacciniaPhoto credit: V. Fulginiti, MD and Logical Images
http://www.bt.cdc.gov/training/smallpoxvaccine/reactions/default.htm
SCID
HypogammaglobulinemiaLymphosarcoma
Lymphoma and PV
FETAL VACCINIAPhoto credit: J. Michael Lane, MD MPH
CDC Teaching slide set Adverse reactions following smallpox vaccination
Fetal vaccinia
Photo credit: J. Michael Lane, MD MPHCDC Teaching slide set Adverse reactions
following smallpox vaccination
Post-vaccination Responsibilities
Careful care of your siteCareful care of your site Stay hydrated – drink fluidsStay hydrated – drink fluids
Adverse reactions:Adverse reactions: Call to reportCall to report Follow-up with your primary care physicianFollow-up with your primary care physician Emergency care if neededEmergency care if needed
Reporting Adverse Events Following Smallpox Vaccine Report – clinically significant or unexpected AesReport – clinically significant or unexpected Aes
When – clinically significant/unexpected AEs within 48 When – clinically significant/unexpected AEs within 48 hours and other AEs within 7 dayshours and other AEs within 7 days
Who can report – SHDs, providers, vaccinees, Who can report – SHDs, providers, vaccinees, manufacturersmanufacturers
How to reportHow to report http://secure.vaers.org/VaersDataEntry.cfmhttp://secure.vaers.org/VaersDataEntry.cfm Fax: 877-721-0366Fax: 877-721-0366 Telephone: 800-822-7967 for formTelephone: 800-822-7967 for form
Next steps
Voluntary program: determine your risk Voluntary program: determine your risk
Vaccination clinics next weekVaccination clinics next week
Post-vaccination training Post-vaccination training Phase 2 vaccinationsPhase 2 vaccinations Prepared for mass vaccination (if event)Prepared for mass vaccination (if event)
Calendar: Vaccination clinics
3/3 Vaccination clinic 13/3 Vaccination clinic 1 3/10 Check “takes” (day 7 clinic 1)3/10 Check “takes” (day 7 clinic 1)
3/6 Vaccination clinic 2 (makeup/overflow)3/6 Vaccination clinic 2 (makeup/overflow) 3/13 Check “takes” (day 7 clinic 2)3/13 Check “takes” (day 7 clinic 2)
Calendar: Post-vax training
Phase 1 Post-vaccination training (6 Phase 1 Post-vaccination training (6 hours) on 3/20hours) on 3/20
Identify and prioritize roles of public Identify and prioritize roles of public health response team member:health response team member:
In event of smallpox In event of smallpox exposure event: (4 hours)exposure event: (4 hours)
As member of vaccination team: As member of vaccination team: (two 1-hour workshops)(two 1-hour workshops)
Calendar: Phase 2 schedule
To be determinedTo be determined
For More Information
CDC Smallpox websiteCDC Smallpox website
www.cdc.gov/smallpoxwww.cdc.gov/smallpox
National Immunization Program website National Immunization Program website www.cdc.gov/nipwww.cdc.gov/nip
Acknowledgements: sources for slides and materials
Anthony J. Carbone, MD, MS, MPH Anthony J. Carbone, MD, MS, MPH The Harvard Center For Public Health PreparednessThe Harvard Center For Public Health Preparedness
Harvard School of Public HealthHarvard School of Public Health
Centers for Disease Control and PreventionCenters for Disease Control and PreventionCertain images supplied by:
Dr. J. Michael LaneDr. Vincent Fulginiti
Dr. Henry KempeDr. John Leedom
NEJMNational Institutes of Health
Logical Images, Inc.
Acknowledgements:
Anthony J. Tomassoni, MD, MS, FACEP, DACMTAnthony J. Tomassoni, MD, MS, FACEP, DACMTMedical DirectorMedical Director
OPHEPOPHEP
Jo E. Linder, MDJo E. Linder, MDMedical Officer, Southern RegionMedical Officer, Southern Region
HHSD/Portland Public HealthHHSD/Portland Public Health
Thank You for Volunteering!